NETCast

Episod

• 
  Beyond the Tumor: Genetics, Cardiac Complications, and the Expanding NET Care Team 10.09.2026 31min

  In this episode of NETCast, we explore two increasingly important, and often underrecognized, aspects of neuroendocrine tumor care: hereditary risk assessment and long-term systemic complications, including carcinoid heart disease.Hosted by Dr. Daniel Halperin and featuring experts in genetic counseling and cardio-oncology, the discussion examines how multidisciplinary NET care teams are evolving beyond traditional oncology models to better support patients across the full continuum of disease.Together, the panel discusses hereditary syndromes, integrating genetic counseling into NET care, recognizing cardiac complications earlier, survivorship considerations, and the importance of communication across multidisciplinary care teams. The conversation also highlights how comprehensive NET programs are increasingly expanding to address the broader systemic and long-term needs of patients living with neuroendocrine tumors. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Beyond the Clinic: What Patients and Caregivers Need Most in NET Care 13.08.2026 35min

  In this episode of NETCast, we explore the patient and caregiver experience beyond the clinic walls and examine what truly patient-centered care looks like within the neuroendocrine tumor community. Hosted by Dr. Daniel Halperin and featuring leaders from the Neuroendocrine Tumor Research Foundation and Neuroendocrine Cancer Foundation, this conversation focuses on the emotional realities of living with NETs, caregiver advocacy, the importance of community and peer support, and how healthcare teams can better support patients and families throughout the disease journey. Together, the panel shares practical insights and personal perspectives on building trust, reducing isolation, and improving quality of life in rare disease care. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Multidisciplinary Management of Advanced NETs: Optimizing Long-Term Tumor Control 23.07.2026 31min

  Recorded live at the NANETS Columbus Regional Conference, this episode of NETCast explores the multidisciplinary strategies that drive long-term tumor control in patients with advanced neuroendocrine tumors (NETs).Hosted by Drs. Jordan Cloyd and Bhavana Konda, the discussion brings together experts in medical oncology, surgical oncology, and gastroenterology to examine how treatment decisions evolve over the course of a patient's disease. Rather than focusing on a single intervention, the conversation highlights the importance of balancing systemic therapy, surgery, endoscopic management, quality of life, and patient goals through coordinated multidisciplinary care.Through practical discussion and real-world perspectives, the panel explores treatment sequencing, the evolving role of cytoreductive surgery, when less invasive management may be appropriate, and how multidisciplinary tumor boards help navigate complex clinical decisions. Together, the panel shares insights into how collaboration across specialties leads to more thoughtful, individualized care and better long-term outcomes for patients living with advanced neuroendocrine tumors. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Beyond the Data: How Physicians Talk to Patients About Uncertainty 27.05.2026 49min

  In this episode of NETCast, host Dr. Emil Lou is joined by a multidisciplinary panel of experts and a patient advocacy perspective to explore one of the most nuanced aspects of neuroendocrine tumor care: how physicians communicate uncertainty when the data are limited, evolving, or open to interpretation.Featuring perspectives from medical oncology, surgical oncology, nuclear medicine, and patient advocacy, the discussion examines the real-world challenges of navigating gray areas in NET care where multiple treatment paths may be reasonable and patient preferences play a critical role. The panel discusses how clinicians approach conversations when evidence is incomplete, communicate risk and treatment options, manage differing opinions within multidisciplinary teams, and build trust with patients facing complex decisions.Together, the group offers candid reflections and practical insights on balancing science, communication, and compassion in modern NET care. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  How Multidisciplinary Tumor Board Functions as the Engine Behind Complex NET Decision-Making 06.04.2026 28min

  In this live recording from the Nashville Regional, we will explore the real-world impact of multidisciplinary NET specialty centers, particularly for patients initially diagnosed or managed in community settings. What structurally changes when a patient transitions from community-based care to an academic institution? And further, what distinguishes a general academic center from a dedicated NET specialty center?This conversation will examine how multidisciplinary tumor board functions as the operational engine behind complex decision-making, the role of pathology reassessment, referral timing, access to specialized imaging and therapies, and how community and specialty centers can collaborate to optimize outcomes for patients with neuroendocrine tumors.The focus will be on systems of care and collaboration, rather than on a specific therapy or guideline update. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Feocromocitoma y Paraganglioma (Spanish podcast on Pheochromocytoma & Paraganglioma) 08.01.2026 1j 10min

  Este podcast médico presenta una discusión entre los Drs. Sarimar Agosto, Alejandro Román-González y Camilo Jiménez sobre el manejo del feocromocitoma y paraganglioma. Manejo multidisciplinario esencial (endocrinología, oncología, cirugía, genética, radiología nuclear). Referir pacientes a centros de excelencia. Cada caso requiere individualización del tratamiento según progresión, localización tumoral y estado global del paciente.  See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Hybrid Neuroendocrine Cancers: Pathology, Grade Transformation, and Emerging Therapies 22.12.2025 35min

  This NETCast episode features Dr. Uday Grewal hosting a discussion with Drs. Aman Chauhan, Renuka Iyer, and Shagufta Shaheen on the complexities of hybrid neuroendocrine cancers. The panel explores transformation cases, mixed histology, and emerging DLL3-targeted therapies with lung cancer and CAR-T expertise. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Hot Topics in NET Clinical Care 15.12.2025 38min

  This NETCast episode from the 2025 NANETS Symposium features Dr. Theodora Dimitra hosting a discussion with Drs. Alexandria Phan, Po H. Ear, Dawn Quelle, and Andrew Bellizzi on a range of hot topics. The panel discusses challenging NET clinical scenarios including biomarkers, GLP-1 medications, and surgical decision-making. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  AI in Healthcare: Transforming NET Care Through Personalized Medicine 08.12.2025 31min

  This episode of NETCast features Dr. Thorvardur Halfdanarson (Mayo Clinic oncologist) and Burt Rosen (patient advocate) discussing artificial intelligence's role in transforming healthcare, particularly for NET patients. Both guests agree AI represents a truly transformative shift—not just another overhyped technology—with potential to revolutionize drug discovery, clinical trial design, and most importantly, move medicine from population-based treatment to individualized care. They also discuss key ethical considerations such as data ownership, patient consent for AI use in care, and ensuring models are trained on diverse populations to avoid amplifying existing biases. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Presidential Perspectives: The Evolution and Future of NET Care 01.12.2025 25min

  This episode of NETcast features a "presidential panel" of three distinguished NANETS leaders: Dr. Jennifer Chan (president 2025, Dana-Farber), Dr. Simran Singh (incoming president, Sunnybrook), and Dr. Thorvardur Halfdanarson (president emeritus, Mayo Clinic). The discussion covers transformative developments in NET management over the past decade, including radiopharmaceuticals, targeted therapies, and the recognition that NETs may be less rare than previously thought. The experts explore the future of alpha and beta particle therapy retreatment protocols, challenges in biomarker development, and the importance of treatment sequencing given disease heterogeneity. The panel also discusses the importance of mentorship and the welcoming nature of the NET community in nurturing early-career researchers, while acknowledging that future progress will likely come through incremental advances and optimal treatment sequencing rather than single breakthrough therapies. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  NET Patient Advocacy: A Multi-Stakeholder Perspective 24.11.2025 29min

  This episode of NETCast features a panel on NET patient advocacy. They explore why advocacy is critical for this rare cancer, discussing challenges patients face at diagnosis, the importance of education and resources, research funding obstacles, and political advocacy efforts. The panel emphasizes that patients should be active participants in advocacy—whether through contacting reprsentatives, supporting research organizations, or engaging in educational initiatives—to make this "invisible" disease visible and drive meaningful change in treatment and outcomes. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Current State of NETs, Successes, and Future Directions in Latin America 09.09.2025 48min

  This podcast episode discusses the current state of neuroendocrine tumors in Latin America, focusing on the challenges and advancements in diagnosis and treatment. Experts from various countries share insights on the importance of education, registration, and multidisciplinary approaches in managing these tumors. The role of international societies like NANETS in supporting research and education is emphasized, along with the need for increased participation in clinical trials and improved access to treatment options for patients. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  The Intersection of Compassion and Burnout in NETs 12.08.2025 29min

  In this conversation, Jason Starr and Jessica Thomas discuss the critical intersection of mental health and oncology. They explore personal experiences with mental health challenges, the prevalence of burnout among healthcare providers, and the importance of resilience and wellness strategies. The discussion also delves into compassion fatigue, the necessity of setting boundaries for self-care, and the value of community support in navigating these challenges. The conversation emphasizes that mental health is a journey and encourages open dialogue about struggles in the healthcare field. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Promising Advances in NEC Research and Treatment 27.05.2025 37min

  In this podcast, Dr. Garima Gupta meets with Dr. Renuka Iyer and Dr. Aman Chauhan to discuss the latest advancements in the treatment of neuroendocrine carcinomas, focusing on the differences between pulmonary and extra pulmonary types, treatment strategies for extensive stage cases, and the challenges faced in treating platinum refractory patients. They highlight the importance of clinical trials and innovative therapies, including DLL3 targeting and oncolytic virus studies, while emphasizing the need for ongoing research and patient participation in trials. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Understanding the COMPETE Study and Its Implications 31.03.2025 34min

  In this episode of the NET Podcast, Dr. Arshad meets with Dr. Soares, Dr. Shaheen, and Dr. Sonbol at the Tucson Regional Conference to discuss the evolving landscape of neuroendocrine tumors, focusing on recent studies such as the COMPETE study and the implications for treatment sequencing and patient care. They explore the importance of individualized treatment plans, the role of new therapies like cabozantinib, and the real-world challenges faced by patients, including financial toxicity. The conversation highlights the need for ongoing research and collaboration in the field. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  Terapias para tumores neuroendocrinos en México 25.02.2025 22min

  ¡Bienvenidos a nuestro primer podcast en español! En este episodio, el Dr. Ismael Domínguez Rosado hablará con la Dra. Cecilia Carreras y la Dra. Mónica Isabel Meneses Medina para revisar la agenda de nuestra Conferencia Regional en la Ciudad de México. Luego, discutirán terapias locales y regionales para tumores endocrinos en México. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  2024 Symposium Abstracts: The Promise of PRRT in Neuroendocrine Tumor Treatment - Recorded November 22nd, 2024 14.01.2025 44min

  In this episode of NETCAST, neuroendocrine experts Dr. Mosalem and Dr. Wahl meet with Taymeyah Al-Toubah discuss the latest advancements in neuroendocrine tumor treatments, focusing on peptide receptor radionuclide therapy (PRRT) with alpha and beta emitters. They delve into the safety and efficacy of new investigational agents, the challenges of hematological toxicity, and the importance of multidisciplinary teams in managing patient care. The conversation highlights the evolving landscape of neuroendocrine tumor therapies and the need for ongoing research and collaboration. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  2024 Symposium Abstracts: New Research Using Biomarkers for Neuroendocrine Tumor Treatment - Recorded November 21st, 2024 07.01.2025 31min

  In this podcast episode, neuroendocrine experts Dr. Liu and Dr. Gujarathi meet with Dr. Phan to discuss the latest advancements in neuroendocrine tumor research, focusing on innovative models for studying G1 and G2 neuroendocrine tumors, the implications of genetic mutations in pancreatic neuroendocrine tumors, and the future of drug screening and treatment protocols. The conversation highlights the importance of developing effective therapies tailored to individual patient profiles and the potential for new biomarkers to guide treatment decisions. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  2024 Symposium Abstracts: Innovative Therapies for Neuroendocrine Tumors - Recorded November 20th, 2024 31.12.2024 18min

  In this episode of NETCAST, leading neuroendocrine experts Dr. Mohammed and Dr. Chauhan meet with Dr. Gangi to discuss their recent studies on innovative therapies for neuroendocrine tumors. Dr. Chauhan presents findings on Peltocetine, a new oral somatostatin receptor agonist, highlighting its efficacy in treating carcinoid syndrome. Dr. Mohammed shares insights on NP101, a combination therapy for metastatic neuroendocrine carcinomas, emphasizing its potential in enhancing treatment outcomes. The conversation explores the future of neuroendocrine cancer treatment, focusing on patient preferences and the importance of ongoing research. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
• 
  2024 Symposium: Bridging the Gap with Patient Advocacy Groups - Recorded November 23rd, 2024 11.12.2024 45min

  In this episode of NETCast, Dr. Jason Starr engages with patient advocacy leaders in the NET community to review highlights and insights from the 2024 NANETS Annual Symposium. Lisa Yen, Jessica Thomas, and Josh Mailman discuss the evolving role of patients in their care, the need for more therapies for neuroendocrine carcinoma, and the significance of building trust between patients and healthcare providers. The panelists share their experiences and strategies for empowering patients and bridging gaps in clinical trials and education. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.